Skip to main content
Premium Trial:

Request an Annual Quote

Fluidigm Sets IPO Pricing at $13.50 per Share

Premium

Fluidigm announced today the pricing of its initial public offering of 5,558,333 shares of its common stock at a price to the public of $13.50 per share.

The pricing comes in at the low end of the anticipated range of $13.50 to $15.50 that Fluidigm disclosed to potential investors in a prospectus filed late last month with the US Securities and Exchange Commission. Fluidigm also said at the time that it anticipated offering 5,172,414 shares of its common stock.

Deutsche Bank and Piper Jaffray are acting as joint book-running managers for the offering. Cowen and Company and Leerink Swann acted as co-managers.

Fluidigm has granted the underwriters an option to purchase up to an additional 833,750 shares of common stock to cover over-allotments, if any.

Fluidigm said that shares of its common stock have been approved to trade on the Nasdaq under the ticker symbol "FLDM."

Fluidigm first disclosed its renewed IPO effort in early December, reviving plans for a public offering that the company put on hiatus in September 2008 amid the economic downturn (PCR Insider, 12/9/10).

In its December preliminary prospectus, Fluidigm said it intends to use net proceeds from the IPO for sales and marketing; to support ongoing product commercialization; for research and product-development activities; to expand its facilities and manufacturing operations; and for working capital and other general corporate purposes.

The South San Francisco, Calif.-based company noted that it may also use a portion of its net proceeds to acquire and invest in complementary products, technologies, or businesses, although it currently has no such agreements or commitments in place.

Fluidigm plays primarily in the genetic analysis, PCR, digital PCR, and next-generation sequencing sample-prep markets. Its products include the BioMark and EP1 systems for digital PCR and SNP analysis; AccessArray platform for sample prep; and Dynamic Array, Digital Array, and Access Array microfluidic chips for use on its analysis systems.

The company also disclosed in December a previously undisclosed collaboration with Novartis Vaccines and Diagnostics to develop digital PCR-based, non-invasive, prenatal molecular diagnostics, initially for fetal aneuploidies.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.